- Ascend Advanced Therapies is expanding its Alachua, Florida, and Munich, Germany facilities to meet growing demand, with new GMP capabilities and quality control enhancements.
- The expansions, which include 500L GMP suite capacity and fill/finish capabilities, are expected to continue through 2025.
Ascend Advanced Therapies has announced a major investment to expand its global infrastructure, targeting growth in its Alachua, Florida, and Munich, Germany facilities. The expansions aim to meet increasing demand in the gene therapy sector.
The Alachua facility is undergoing significant upgrades, including the addition of GMP suite capacity up to 500L, with plans for future larger-scale bioreactors. The facility will also integrate new fill/finish capabilities and allocate additional space for GMP warehousing and process development labs.
In Munich, Ascend is bolstering its quality control (QC) testing, analytical, and process development capacity to support growing industry needs. The expansion of both facilities is expected to continue into 2025.
Mike Stella, CEO at Ascend, stated, “As our footprint grows, we will iterate over 2 decades of therapeutic AAV expertise into a connected global footprint with cutting-edge, enabling technologies, and analytics for our clients.”
Overview of outsourcing trends 
